Core Viewpoint - PharmAla Biotech Holdings Inc. has entered into a Supply & Data Agreement with Nautilus Sanctuary Inc. to provide LaNeo™ MDMA for a Phase 2 clinical trial focused on treating post-traumatic stress in frontline healthcare workers and first responders [1][2]. Group 1: Agreement Details - PharmAla will supply LaNeo™ MDMA to Nautilus Sanctuary for an open-label clinical trial titled "An Open Label Study to Treat Post-Traumatic Stress in Frontline Healthcare Workers and First Responders Using MDMA-Assisted Therapy" [2]. - In exchange for the MDMA supply, Nautilus Sanctuary will grant PharmAla a perpetual, non-exclusive license to the clinical trial data, which includes pseudonymized and de-identified raw data sets and analysis of safety and efficacy [2]. Group 2: Company Background - PharmAla Biotech is focused on the research, development, and manufacturing of MDXX class molecules, including MDMA, and aims to alleviate the global backlog of clinical-grade MDMA for trials and commercial sales [5]. - The company is recognized as a "regulatory first" organization, emphasizing strong relationships with regulators to succeed in the psychedelics industry [5]. - PharmAla has established what it believes to be North America's first cGMP MDMA value chain, which includes GMP manufacturing of Active Pharmaceutical Ingredient (API) and drug product formulation [5]. Group 3: Clinical Research Initiatives - The agreement with Nautilus Sanctuary is part of PharmAla's innovative supply-for-data model, which aims to create significant value for both parties involved [3]. - The clinical data generated from this agreement will contribute to PharmAla's portfolio of evidence supporting the safety and efficacy of LaNeo™ MDMA [3]. - PharmAla has also completed the shipment of LaNeo MDMA to University College London for a previously announced clinical trial [4].

Core Insights - PharmAla Biotech Holdings Inc. has entered into an agreement with Spaulding Rehabilitation to provide LaNeo™ MDMA for a clinical trial focused on MDMA-assisted therapy for fibromyalgia [1][2] Company Overview - PharmAla Biotech is a biotechnology company specializing in the research, development, and manufacturing of MDXX class molecules, including MDMA [8] - The company aims to alleviate the backlog of generic, clinical-grade MDMA for clinical trials and commercial sales, while also developing novel drugs in the same class [8] - PharmAla is currently the only provider of clinical-grade MDMA for patient treatments outside of clinical trials [8] Clinical Trial Details - The clinical trial, titled "Hyperscan Neuroimaging to Reveal the Brain Mechanisms Supporting Analgesia Following MDMA-Assisted Therapy in Fibromyalgia," will be led by Dr. Vitaly Napadow at Spaulding Rehabilitation [2][3] - The study will utilize advanced hyperscan neuroimaging techniques to explore the brain mechanisms involved in pain relief from MDMA-assisted therapy, marking a new application of MDMA beyond PTSD treatment [3][4] Research Collaboration - Under the agreement, PharmAla will provide LaNeo™ MDMA at no cost, in exchange for a license to the study results [2][5] - Spaulding Rehabilitation will deliver comprehensive study results to PharmAla within 90 days of study completion, including group means and regression analysis plots [5] - PharmAla will leverage the findings for potential regulatory submissions, while Spaulding retains the right of first publication in a peer-reviewed journal [5]

Core Viewpoint - PharmAla Biotech Holdings Inc. has entered into a binding supply agreement with Amsterdam University Medical Center for the provision of LaNeo™ 40mg MDMA capsules for a proposed clinical trial [1][4]. Group 1: Agreement Details - The agreement stipulates that PharmAla will supply LaNeo™ 40mg capsules in a new single-capsule packaging format [2]. - A three-year stability testing program is included in the agreement, aimed at generating new stability data for the single-capsule dosage form [2][3]. - The stability data is essential for developing commercial-grade blister packaging, which is the standard for pharmaceutical distribution [3]. Group 2: Strategic Importance - The stability testing program will support PharmAla's broader commercial strategy by enabling more efficient distribution to clinical trial sites and commercial partners globally [3]. - The agreement expands PharmAla's European clinical footprint and is contingent upon executing a Quality Agreement with the Clinical Pharmacy of Amsterdam UMC [4]. - PharmAla aims to leverage the stability data for future commercial-grade packaging of LaNeo™ MDMA, marking a significant step towards a commercial-grade product [4]. Group 3: Company Background - PharmAla Biotech Holdings Inc. focuses on the research, development, and manufacturing of MDXX class molecules, including MDMA, and is the only company provisioning clinical-grade MDMA for patient treatments outside of clinical trials [6]. - The company was founded to alleviate the backlog of generic, clinical-grade MDMA and to develop novel drugs in the same class [6]. - PharmAla's research and development unit has completed proof-of-concept research into several intellectual property families, including its lead drug candidate ALA-002 [6].

Core Viewpoint - PharmAla Biotech Holdings Inc. announces changes to its Board of Directors, including the resignation of Dr. Malik Slassi and the appointment of Mr. Lennie Ryer, aiming to enhance the board's expertise as the company progresses in its development [1][2][3]. Company Overview - PharmAla Biotech Holdings Inc. is focused on the research, development, and manufacturing of MDXX class molecules, including MDMA, with a dual focus on alleviating the backlog of clinical-grade MDMA for trials and commercial sales, as well as developing novel drugs [4]. - The company is currently the only provider of clinical-grade MDMA for patient treatments outside of clinical trials and has completed proof-of-concept research into several intellectual property families, including its lead drug candidate ALA-002 [4]. Board Changes - Dr. Malik Slassi has resigned from the board effective February 9, 2026, after four years of support and insight during the company's early stages [2][3]. - Mr. Lennie Ryer, a seasoned financial executive with extensive experience in corporate finance and governance, has been appointed to the board, bringing valuable expertise as the company enters a new phase of development [3].

Core Viewpoint - PharmAla Biotech Holdings Inc. has entered into an agreement with Østfold Hospital Trust of Norway to supply LaNeo™ MDMA for research into its potential as a treatment for Major Depressive Disorder [1][2] Group 1: Agreement Details - The agreement includes financial and data-sharing provisions, with PharmAla aiming to ship LaNeo MDMA Clinical Research Materials to Østfold Hospital Trust as soon as regulatory approvals are obtained [2][3] - Østfold Hospital Trust selected PharmAla after a competitive review, citing the company's professionalism and understanding of regulatory and scientific requirements for clinical research [3] Group 2: Company Background - PharmAla is focused on the research, development, and manufacturing of MDXX class molecules, including MDMA, and aims to alleviate the global backlog of clinical-grade MDMA for trials and commercial sales [5] - The company is the only provider of clinical-grade MDMA for patient treatments outside of clinical trials and has completed proof-of-concept research into several drug candidates [5]

Core Viewpoint - PharmAla Biotech Holdings Inc. is advancing its development of LaNeo™ MDMA and aims to initiate Phase 2a/b clinical trials in Australia, driven by increasing demand and reimbursement approvals for medical treatments using LaNeo MDMA [2]. Financial Highlights - The company has reported an increase in customer deposits, with a total of $276,000 as of August 31, 2025, up from $209,000 in 2024, and $433,000 as of November 30, 2025, up from $276,000 [7]. - Recognized revenue for the year-end 2025 was $83,000, and for Q1 2026, it was $68,000, indicating ongoing revenue generation alongside growing deposits [7]. Development and Strategy - The company has filed a short-form prospectus and secured a lending partner in Australia, which will support its clinical trial and development efforts [4]. - PharmAla is focused on alleviating the global backlog of generic, clinical-grade MDMA and developing novel drugs within the MDXX class [4].

Core Insights - PharmAla Biotech Holdings Inc. has contracted with a UK-based CDMO for the manufacture of its ALA-002 drug substance, marking a significant step towards executing its Phase 2 clinical trial in 2026 [1][2] - ALA-002 is a patented, novel, non-racemic MDMA formulation aimed at treating Social Anxiety Disorder, with clinical research set to begin in 2026 [2] - The company has completed one of two shipments of LaNeo MDMA to the Parsons Research Center for Psychedelic Healing at Mount Sinai for clinical research purposes [3] Company Overview - PharmAla Biotech Holdings Inc. focuses on the research, development, and manufacturing of MDXX class molecules, including MDMA, and aims to alleviate the global backlog of clinical-grade MDMA for trials and commercial sales [4] - The company is recognized as the only provider of clinical-grade MDMA for patient treatments outside of clinical trials, emphasizing its commitment to regulatory relationships [4] - PharmAla's research and development unit has completed proof-of-concept research into several intellectual property families, including ALA-002, its lead drug candidate [4]

Core Viewpoint - PharmAla Biotech Holdings Inc. has filed a final short form base shelf prospectus to provide flexibility for financing opportunities over a 25-month effective period, allowing the company to issue various securities as needed [1][2][4] Group 1: Prospectus Details - The prospectus has been filed in all provinces and territories in Canada, enabling the company to offer common shares, warrants, units, subscription receipts, debt securities, or any combination of these securities [2] - The company may utilize the prospectus for "at-the-market distribution," allowing securities to be sold through the Canadian Securities Exchange or other trading markets [3] - Currently, there are no immediate plans to issue any securities under the prospectus, and specific terms will be outlined in a prospectus supplement if the company decides to proceed [4] Group 2: Loan Facility with Radium Capital - PharmAla's subsidiary, PharmAla Biotech Australia, has signed a term sheet with Radium Capital for a loan facility based on expected Research and Development Tax Incentive refunds [5] - The loan facility allows for up to 80% of the expected RDTI refund to be advanced once qualifying expenses are incurred, with each tranche secured by the related RDTI refund [5] - The CEO emphasized that this loan facility presents an opportunity to develop intellectual property without exposing it to securitization risk, aligning with the company's clinical trial strategy in Australia [6] Group 3: Strategic Goals - The CFO highlighted that securing efficient, low-risk debt funding will help optimize future tax incentives and drive cost efficiency in planned clinical trials [7] - PharmAla aims to alleviate the global backlog of generic, clinical-grade MDMA for clinical trials and commercial sales while developing novel drugs in the same class [7]

Core Insights - PharmAla Biotech Holdings Inc. has launched NEXUS, a new tool aimed at connecting prescribers, therapists, and clinic managers involved in MDMA-assisted therapy, enhancing the care delivery process [1][2][3] Group 1: NEXUS Tool - NEXUS is designed to facilitate communication and data sharing among the entire MDMA-assisted therapy team, including prescribers, therapists, and clinic managers [2][3] - The tool aims to address the challenges faced by prescribers and other stakeholders in navigating regulatory pathways and improving patient care [2][3] Group 2: Leadership Changes - Farnoud Kazemzadeh has been appointed as the Chief Operating Officer of PharmAla, bringing extensive experience in scaling businesses [3] - Dr. Harriet De Wit has resigned from PharmAla's Board of Directors, with the company expressing gratitude for her contributions [4] Group 3: Company Overview - PharmAla focuses on the research, development, and manufacturing of MDXX class molecules, including MDMA, and is the only company providing clinical-grade MDMA for patient treatments outside of clinical trials [5] - The company aims to alleviate the backlog of clinical-grade MDMA for trials and commercial sales while developing novel drugs in the same class [5]

Core Insights - PharmAla Biotech Holdings Inc. has successfully shipped its LaNeo™ MDMA to Johns Hopkins University, marking a significant advancement in MDMA research in the United States [1][2] - The CEO of PharmAla emphasizes the importance of this delivery for clinical trials, which have faced challenges in sourcing investigational medical products [2] - LaNeo™ MDMA is now approved for use in the continental US and is already utilized in clinical trials globally [2] Company Overview - PharmAla Biotech is focused on the research, development, and manufacturing of MDXX class molecules, including MDMA, with a dual aim of alleviating the backlog of clinical-grade MDMA and developing novel drugs [4] - The company is currently the only provider of clinical-grade MDMA for patient treatments outside of clinical trials [4] - PharmAla's research unit has completed proof-of-concept research for several drug candidates, including ALA-002, its lead candidate [4] Financial Activities - The company has settled $150,000 in debt by issuing 1,666,667 common shares at a deemed price of $0.09 per share [3]